Target Price | $52.02 |
Price | $47.14 |
Potential |
10.35%
register free of charge
|
Number of Estimates | 25 |
25 Analysts have issued a price target Bristol-Myers Squibb 2026 .
The average Bristol-Myers Squibb target price is $52.02.
This is
10.35%
register free of charge
$71.40
51.46%
register free of charge
$33.43
29.08%
register free of charge
|
|
A rating was issued by 33 analysts: 10 Analysts recommend Bristol-Myers Squibb to buy, 21 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Bristol-Myers Squibb stock has an average upside potential 2026 of
10.35%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 48.30 | 47.71 |
7.32% | 1.22% | |
EBITDA Margin | 42.27% | 37.20% |
4.43% | 12.00% | |
Net Margin | -18.53% | 28.07% |
203.90% | 251.52% |
28 Analysts have issued a sales forecast Bristol-Myers Squibb 2025 . The average Bristol-Myers Squibb sales estimate is
This results in the following potential growth metrics:
17 Analysts have issued an Bristol-Myers Squibb EBITDA forecast 2025. The average Bristol-Myers Squibb EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
28 Bristol-Myers Squibb Analysts have issued a net profit forecast 2025. The average Bristol-Myers Squibb net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -4.41 | 6.58 |
214.25% | 249.21% | |
P/E | 7.16 | |
EV/Sales | 2.76 |
28 Analysts have issued a Bristol-Myers Squibb forecast for earnings per share. The average Bristol-Myers Squibb EPS is
This results in the following potential growth metrics and future valuations:
Bristol-Myers Squibb...
Analyst | Rating | Action | Date |
---|---|---|---|
Citigroup |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Jul 10 2025 |
Jefferies |
Locked
➜
Locked
|
Locked | Apr 23 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Apr 23 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Apr 22 2025 |
UBS |
Locked
➜
Locked
|
Locked | Apr 11 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
Analyst Rating | Date |
---|---|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 01 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jul 10 2025 |
Locked
Jefferies:
Locked
➜
Locked
|
Apr 23 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Apr 23 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Apr 22 2025 |
Locked
UBS:
Locked
➜
Locked
|
Apr 11 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.